期刊文献+

两种常用抗肝纤维化中成药临床疗效的比较 被引量:5

Comparison of therapeutic efficacy between two Chinese patent drugs for liver fibrosis
下载PDF
导出
摘要 目的比较扶正化瘀胶囊和安络化纤丸临床抗肝纤维化作用。方法选择99例肝纤维化患者,随机分为两组,分别采用扶正化瘀胶囊治疗51例和安络化纤丸治疗48例,疗程为12个月,观察两组治疗前后Fibroscan值、肝纤维化四项、肝脏彩色超声以及肝脏病理学等的变化。结果经治疗后,扶正化瘀胶囊组Fibroscan值为8.25 KPa、HA为143.4 ng/mL、LN为95.9 ng/mL、PC-III为109.3 ng/mL、Ⅳ-C为72.1 ng/mL、门静脉内径为10.13 mm、脾脏厚度为38.40 mm。安络化纤丸组Fibroscan值为13.04 kPa、HA为208.7 ng/mL、LN为155.5 ng/mL、PC-III为110.0ng/mL、Ⅳ-C为117.5 ng/mL、门静脉内径为12.61 mm、脾脏厚度为45.01 mm。两组相比差异有统计学意义(P<0.05),此外扶正化瘀胶囊改善纤维化分级具有显著的效果(P<0.05)。结论与安络化纤丸相比,扶正化瘀胶囊具有更好的临床疗效。 Objective To compare the therapeutic efficacy between Fuzheng Huayu capsule and AnLuo HuaXian pill.Methods Ninety-nine patients with liver fibrosis were randomly divided into two groups.Group one received Fuzheng Huayu capsule treatment and group two received AnLuo HuaXian pill treatment.All patients received treatment for 12 months.Fibroscan value,liver fibrosis indexes,color ultrasound images and liver pathology were measured before and after treatment.Results After treatment,the Fibroscan value of Fuzheng Huayu capsule group was 8.25 KPa, liver fibrosis indexes were HA: 143.4 ng/mL、LN:95.9 ng/mL、PC-III: 109.3 ng/mL、Ⅳ-C:72.1 ng/mL, respectively.The inside diameter of portal vein was 10.13 mm and thickness of spleen was 38.40 mm.The Fibroscan value of AnLuo HuaXian pill group was 13.04 kPa,liver fibrosis indexes were HA:208.7 ng/mL、LN:155.5 ng/mL、PC-III:110.0 ng/mL、Ⅳ-C:117.5 ng/mL,respectively.The inside diameter of portal vein was 12.61 mm and thickness of spleen was 45.01 mm.There were significant differences in the indexes above between the two groups (P 〈0.05 ), What is more,Fuzheng Huayu capsule showed a better effect on improving the fibrosis grades (P 〈0.05).Conclusion Fuzheng Huayu capsule is more effective for liver fibrosis treatment than AnLuo HuaXian pill.
出处 《肝脏》 2014年第5期332-334,共3页 Chinese Hepatology
关键词 肝纤维化 临床疗效 FIBROSCAN 扶正化瘀胶囊 Liver fibrosis Therapeutic efficacy Fibroscan value Fuzheng Huayu capsule
  • 相关文献

参考文献6

二级参考文献32

  • 1梁尧,刘强,林寿宁.扶正化瘀法抗肝纤维化的研究进展[J].陕西中医学院学报,2006,29(1):66-67. 被引量:15
  • 2无.慢性乙型肝炎防治指南[J].实用肝脏病杂志,2006,9(1):8-18. 被引量:825
  • 3贾继东,胡中杰.抗肝纤维化治疗的共识与争议[J].国际消化病杂志,2006,26(3):147-148. 被引量:24
  • 4朱蔚岗,移军,周稳兰.扶正化淤胶囊治疗慢性乙型肝炎肝纤维化的疗效观察[J].淮海医药,2007,25(1):83-83. 被引量:16
  • 5Prabhakar SS.Role of nitric oxide in diabetic nephropathy.Semin Nephrol,2004,24(4):333-344.
  • 6Friedman SL, Bansal MB. Hepatology, 2006, 43(supl 2) : S82
  • 7Van Zonneveld M, Zondervan PE, Cakaloglu Y, et al, Peg- interferon improves liver histology in patients with HBeAg-positire chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int, 2006; 26:399 -405
  • 8Dienstag JL, Goldin RD, Heathcote EJ, et al. Histologicaloutcome during long term lamivudine therapy. Gastroenterology,2003, 124:105- 117
  • 9Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Seminin Liver Dis, 2001, 21:437- 451
  • 10Weiner FR, Giambrone MA, Czaja MJ, et al, Ito2 cell gene expression and collagen regulation, Hepatology, 1990, 11:111-117

共引文献653

同被引文献75

引证文献5

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部